DVAX Stock Overview
A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Dynavax Technologies Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$10.75 |
52 Week High | US$15.15 |
52 Week Low | US$9.74 |
Beta | 1.28 |
11 Month Change | -3.85% |
3 Month Change | -2.36% |
1 Year Change | -25.14% |
33 Year Change | -11.38% |
5 Year Change | 186.67% |
Change since IPO | -88.56% |
Recent News & Updates
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Recent updates
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28Dynavax: A Coronavirus Growth Story
Jan 17Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 18The Momentum Investor: Spotlight On Dynavax Technologies
Oct 25Dynavax And TLR Biology: Long-Delayed But Outstanding Success
Oct 16These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well
Oct 02Shareholder Returns
DVAX | US Biotechs | US Market | |
---|---|---|---|
7D | -3.9% | -4.9% | -5.7% |
1Y | -25.1% | 11.5% | 14.1% |
Return vs Industry: DVAX underperformed the US Biotechs industry which returned 13.1% over the past year.
Return vs Market: DVAX underperformed the US Market which returned 14.1% over the past year.
Price Volatility
DVAX volatility | |
---|---|
DVAX Average Weekly Movement | 5.3% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 14.6% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: DVAX has not had significant price volatility in the past 3 months.
Volatility Over Time: DVAX's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 408 | Ryan Spencer | www.dynavax.com |
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.
Dynavax Technologies Corporation Fundamentals Summary
DVAX fundamental statistics | |
---|---|
Market cap | US$1.32b |
Earnings (TTM) | US$17.18m |
Revenue (TTM) | US$249.69m |
82.0x
P/E Ratio5.6x
P/S RatioIs DVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DVAX income statement (TTM) | |
---|---|
Revenue | US$249.69m |
Cost of Revenue | US$97.18m |
Gross Profit | US$152.51m |
Other Expenses | US$135.34m |
Earnings | US$17.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.13 |
Gross Margin | 61.08% |
Net Profit Margin | 6.88% |
Debt/Equity Ratio | 48.4% |
How did DVAX perform over the long term?
See historical performance and comparison